New solution to boost RNA drug development

Coronavirus RNA strand

Benchling has launched its first full set of capabilities for designing, modeling, and studying both natural and chemically modified RNA in a single solution.

As the biopharmaceutical industry increases its focus on developing RNA therapeutics, the new RNA solution could help R&D organisations accelerate the delivery of drug candidates.

Following the successful deployment of RNA technology in the Pfizer-BioNTech and Moderna Covid-19 vaccines, biopharma companies have shifted their pipelines to uncover therapeutic opportunities with RNA and mRNA.

Nearly half (44%) of top 50 global biopharma companies are involved in RNA work through their own pipelines, M&A, or strategic alliances, according to GlobalData.

RNA therapeutics include a diverse group of therapeutic molecules that range from mRNA vaccines to antisense oligos, RNA-based gene therapy, and guide RNA-based CRISPR complexes. 

The function of these molecules, combined with the ability to adjust key properties through chemical modification or conjugation, has opened up novel ways of treating and preventing diseases. 

“We’re at a tipping point for RNA therapeutics, having figured out tough challenges like durability and stability, the industry is now looking for the right tools to accelerate RNA R&D,” said Ashu Singhal, co-founder and President of Benchling.

“Covid vaccines were really just the beginning – as we put more tools in the hands of scientists to help support their RNA therapeutics R&D, this field will really take off.”

Suggested Reading

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free